Niagen Bioscience (NAGE) Goodwill & Intangibles (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Goodwill & Intangibles of $5.5 million for Q1 2026, up 1603.42% year-over-year from $322000.0 in Q1 2025, and down 3.09% quarter-over-quarter from $5.7 million in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Goodwill & Intangibles (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Goodwill & Intangibles for 15 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 1603.42% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (up 1603.42% YoY), while the FY2025 annual figure was $5.7 million, up 1476.6% from the prior year.
- Goodwill & Intangibles retreated to $5.5 million in Q1 2026 per NAGE's latest filing, from $5.7 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $5.7 million in Q4 2025 and bottomed at $246000.0 in Q3 2025.
- Historically, Goodwill & Intangibles has averaged $1.1 million across 5 years, with a median of $552000.0 in 2023.
- Annual changes were most pronounced in 2025 — Goodwill & Intangibles sank 38.04% — and 2026, when it surged 1603.42%.
- Niagen Bioscience's Goodwill & Intangibles stood at $671000.0 in 2022, then dropped by 23.99% to $510000.0 in 2023, then slipped by 29.61% to $359000.0 in 2024, then jumped by 1476.6% to $5.7 million in 2025, then dropped by 3.09% to $5.5 million in 2026.
- Business Quant data shows NAGE's Goodwill & Intangibles at $5.5 million in Q1 2026, $5.7 million in Q4 2025, and $246000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Mn |
| Mar 31, 2026 | 5.49 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 246,000.00 |
| Jun 30, 2025 | 284,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 359,000.00 |
| Sep 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 472,000.00 |
| Dec 31, 2023 | 510,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 591,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 671,000.00 |
| Sep 30, 2022 | 714,000.00 |
| Jun 30, 2022 | 758,000.00 |
| Mar 31, 2022 | 808,000.00 |
| Dec 31, 2021 | 857,000.00 |
| Sep 30, 2021 | 908,000.00 |